Imjudo (tremelimumab-actl)

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]

Info: nonproprietary name = tremelimumab-actl

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

hepatocellular CA, unresectable

[<30 kg]

Dose: 4 mg/kg/dose IV x1 on day 1 of cycle 1; Info: use with durvalumab

[>30 kg]

Dose: 300 mg IV x1 on day 1 of cycle 1; Info: use with durvalumab

non-small cell lung CA, metastatic

[<30 kg]

Dose: 1 mg/kg/dose IV q3wk x4 cycles on wk 0, 3, 6, 9, then 1 mg/kg/dose IV x1 on wk 16; Max: 5 doses; Info: for patients with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[>30 kg]

Dose: 75 mg IV q3wk x4 cycles on wk 0, 3, 6, 9, then 75 mg IV x1 on wk 16; Max: 5 doses; Info: for patients with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin <3x ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.